RO7795068

DRUG2 trials

Sponsors

F. Hoffmann-La Roche AG

Conditions

Obesity or Overweight Without Type 2 DiabetesObesity or Overweight and Type 2 Diabetes

Phase 3

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes

Not yet recruitingCTIS2025-523104-71-00

F. Hoffmann-La Roche AGObesity or Overweight Without Type 2 Diabetes

Target: 486Updated: 2026-05-08

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes

Not yet recruitingCTIS2025-523106-32-00

F. Hoffmann-La Roche AGObesity or Overweight and Type 2 Diabetes

Target: 273Updated: 2026-05-13